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Abstract: Small vessel (,3 mm) coronary artery disease is common and has been identified 
as independent predictor of restenosis after percutaneous coronary intervention. It remains 
controversial whether bare-metal stent (BMS) implantation in small vessels has an advantage 
over balloon angioplasty in terms of angiographic and clinical outcomes. Introduction of 
drug-eluting stent (DES) has resulted in significant reduction in restenosis and the need for 
repeat revascularization. Several DESs have been introduced resulting in varying reduction in 
outcomes as compared with BMS. However, their impact on outcomes in small vessels is not 
clearly known. It is expected that DES could substantially reduce restenosis in smaller vessels. 
Large, randomized studies are warranted to assess the impact of different DESs on outcomes 
in patients with small coronary arteries.
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Introduction
Coronary artery disease (CAD) is the leading cause of mortality and morbidity 
in the Western world.1 Percutaneous coronary intervention (PCI) utilizing balloon 
angioplasty and stenting is a predominant treatment strategy for patients with CAD. 
Lesions involving the small coronary arteries (with a diameter of ,3 mm) are the 
most relevant in terms of prevalence, and they account for around 40%–50% of all 
coronary stenosis.2 Atherosclerosis of small arteries remains a major challenge to 
revascularization procedures, as coronary artery bypass grafting is limited by high 
rates of technical failure,3 and PCI is associated with an increased risk of restenosis 
and adverse outcome. Small coronary vessel angioplasty remains the independent 
predictor of repeat revascularization and adverse cardiac events.2,4,5 Percutaneous 
treatment of CAD has evolved from percutaneous balloon angioplasty to bare-metal 
stent (BMS) and more recently to drug-eluting stent (DES) implantation. As compared 
with balloon angioplasty, BMS prevents both early elastic recoil and late vascular 
remodeling in large vessels (.3 mm).6–10 However, this benefit is not shown in small 
coronary vessels (,3 mm).11–14 Stent implantation results in arterial injury, initiating 
a vasculoproliferative cascade with smooth muscle cell proliferation and migration 
resulting in neointimal hyperplasia. The amount of neointimal hyperplasia is largely 
independent of vessel size, and thus, late luminal loss, an angiographic measure of 
neointimal hyperplasia, is similar across a wide range of vessel diameters.15,16 Also, 
small vessels are more prone to restenosis than larger vessels because they are less 
able to accommodate neointimal tissue without compromising blood flow.17Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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In this review, we describe the impact of balloon 
  angioplasty, BMSs, and DESs on the outcomes after small 
vessel coronary intervention.
BMS vs balloon angioplasty  
in small vessels
Several randomized trials have compared stenting and per-
cutaneous transluminal coronary angioplasty (PTCA), in 
terms of clinical and angiographic outcomes, in coronary 
arteries with a reference vessel diameter (RVD) of ,3 mm. 
Agostoni et al18 evaluated these outcomes in a meta-analysis, 
and they included 13 studies involving 4,383 randomized 
patients: 2,097 to PTCA and 2,286 to stenting. The studies 
showing mortality, myocardial infarction (MI) rates, target 
lesion revascularization (TLR), and combined major adverse 
cardiac events (MACE) are shown in Table 1.
The mean age of patients in these studies was 62.1 ± 10 
years, with 77.2% men and 28.9% with diabetes. BMSs were 
used in 6 trials (Park et al12 ISAR-SMART, BESMART, 
SISA, RAP, CHIVAS), whereas a stent coated with heparin 
(SISCA, COAST, Kinsara et al)21 or silicon carbide (SVS) or 
phosphorylcholine (ISAR-SMART,   LASMAL, LASMAL 11) 
was used in the remainder. RVD was 2.33 ± 0.29 mm in the 
stent group and 2.31 ± 0.29 mm in PTCA group. The mean 
lesion length was 10.1 ± 5.2 mm, and crossover rate was 
22.2% among PTCA group. Postprocedural mean diameter 
stenosis and minimal luminal diameter were significantly 
better after stenting as compared with PTCA.
The follow-up period ranged from 6–16 months. Death 
and MI rates did not differ significantly between groups 
(1.3% and 3.1% in the stent group vs 1.7% and 4.2% after 
PTCA, respectively). Stenting showed a significant reduction 
of the risk of TLR when compared with PTCA group (14.9% 
vs 18.7%, respectively). However, authors have mentioned 
that there was significant heterogeneity among the trials. 
Among the studies where optimal PTCA result (diameter 
stenosis ,20%) was achieved, there was no   difference in the 
repeat TLR rates (15% vs 16.7%). On the   contrary, among 
trials in which a suboptimal PTCA result was achieved, 
stenting resulted in significant   reduction of repeat TLR rates 
Table 1 Comparison of angiographic characteristics, death, MI, TLR, and MACEs, following BMS and balloon angioplasty
Study Total No. of  
patients
RVD (mm) BMS vs balloon angioplasty
Death (%) 
OR (95% CI)
MI (%) 
OR (95% CI)
TLR (%) 
OR (95% CI)
MACE (%) 
OR (95% CI)
Park et al12 120 ,3.0 0.0 vs 0.0 
NA
1.6 vs 3.2 
0.49 (0.04–5.57)
3.3 vs 5.0 
0.66 (0.11–4.07)
5.0 vs 8.3 
0.58 (0.13–2.54)
ISAR-SMART11  404 2.0–2.8 0.9 vs 1.5 
0.66 (0.11–3.93)
3.4 vs 3.0 
1.15 (0.38–3.48)
20.1 vs 16.5 
1.27 (0.77–2.11)
23.0 vs 19.5 
1.28 (0.79–2.06)
BESMART13 381 ,3.0 0.52 vs 2.1 
0.24 (0.03–2.19)
4.6 vs 5.8 
0.80 (0.32–1.97)
13.5 vs 23.8 
0.50 (0.29–0.85)
17.1 vs 29.6 
0.49 (0.30–0.80)
SISA19 351 2.3–2.9 0.6 vs 0.5 
1.08 (0.07–17.36)
4.1 vs 9.8 
0.39 (0.16–0.97)
20.7 vs 24.7 
0.80 (0.48–1.31)
20.7 vs 25.2 
0.77 (0.47–1.27)
SISCA14 145 2.1–3.0 1.3 vs 1.4, 0.96 
(0.06–15.63)
2.7 vs 1.4 
1.94 (0.17–21.93)
9.4 vs 22.5 
0.36 (0.14–0.94)
9.4 vs 23.9 
0.33 (0.13–0.86)
COAST20 588 2.0–2.6 1.0 vs 0.0 
4.52 (0.24–84.33)
0.5 vs 1.0 
0.49 (0.07–3.53)
10.6 vs 14.3 
0.71 (0.43–1.19)
11.7 vs 15.3 
0.73 (0.44–1.20)
Kinsara et al21 202 ,2.5 1.0 vs 0.0 
3.35 (0.13–83.11)
6.2 vs 6.6 
0.94 (0.31–2.91)
12.5 vs 23.5 
0.64 (0.45–0.92)
19.7 vs 30.1 
0.57 (0.30–1.09)
SVS22 496 2.0–3.0 2.4 vs 2.4 
0.98 (0.31–3.09)
4.8 vs 3.6 
1.33 (0.55–3.21)
18.8 vs 14.2 
1.40 (0.97–2.25)
23.2 vs 18.6 
1.31 (0.85–2.03)
RAP23 426 2.2–2.7 0.47 vs 1.4 
0.33 (0.3–3.23)
0.9 vs 1.4 
0.67 (0.11–4.06)
12.2 vs 22.4 
0.48 (0.29–0.91)
13.6 vs 25.2 
0.47 (0.29–0.77)
CHIVAS24 302 ,3.0 0 vs 2.5 
0.11 (0.01–2.11)
0 vs 0.6  
0.34 (0.01–8.53)
10.8 vs 14.9 
0.69 (0.35–1.37)
10.8 vs 18.1 
0.55 (0.28–1.06)
ISAR-SMART II25 502 ,2.5 3.9 vs 3.6 
1.10 (0.44–2.75)
3.9 vs 4.0 
0.98 (0.40–2.91)
20.1 vs 20.5 
0.98 (0.63–1.51)
26.8 vs 26.9 
1.0 (0.67–1.48)
LASMAL26 246 2.0–2.9 0.8 vs 3.27 
0.24 (0.03–2.18)
5.6 vs 9.0 
0.60 (0.22–1.61)
15.3 vs 20.4 
0.70 (0.36–1.35)
16.9 vs 27.8 
0.53 (0.29–0.97)
LASMAL II27 220 2.0–2.9 1.8 vs 1.8, 0.98 
(0.14–7.10)
6.3 vs 7.3 
0.85 (0.30–2.43)
15.3 vs 14.6 
1.05 (0.50–2.20)
18.0 vs 22.0 
0.78 (0.40–1.51)
Total 4,383 ,3.0 1.3 vs 1.7 
0.81 (0.48–1.36)
3.1 vs 4.2 
0.90 (0.58–1.11)
15.5 vs 18.8 
0.76 (0.61–0.95)
18.2 vs 22.7 
0.71 (0.57–0.90)
Abbreviations: MI, myocardial infarction; TLR, target lesion revascularization; MACEs, major adverse cardiac events; BMS, bare-metal stent; RVD, reference vessel 
diameter; OR, odds ratio; CI, confidence interval.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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(14.8% vs 20.4%). MACE rates were higher in PTCA group 
(17.6% vs 22.7%) and were mainly driven by repeat TLR. 
Angiographic follow-up was performed in 81.9% of the 
patients, and the angiographic restenosis was seen in 27.8% 
patients in stent group   compared with 35.8% in the PTCA 
group with significant heterogeneity. Optimal PTCA group 
has similar angiographic restenosis rates as stent group.
Therefore, stenting appears safe with small vessel CAD 
and significantly reduces angiographic restenosis and repeat 
revascularization rates. However, optimal PTCA in this group 
of patients have achieved comparable results to BMS implan-
tation. The revascularization rates remain high with PTCA or 
BMS implantation in patients with small vessel CAD.
BMS vs DES in small vessels
Paclitaxel-eluting stents vs BMS  
in small vessels
There are no dedicated trials comparing paclitaxel-eluting 
stent (PES) and BMS in small coronary arteries. However, 
large PES trials have described substudy results in small 
vessels. In TAXUS IV trial,28 there were 176 patients with 
RVD , 2.5 mm randomized to PES and BMS. Angiographic 
restenosis rate and 12-month TLR rate in the PES group were 
significantly lower than that in the BMS group, respectively 
(10.2% and 5.6% vs 38.5% and 20.6%; P , 0.001).
In the TAXUS V trial,29 more patients with complex 
lesions were investigated. In the patient group treated with 
the 2.25-mm stent, both PES and BMS have similar acute 
outcomes. However, at the 9-month follow-up, the angio-
graphic restenosis rates and TLR rates were significantly 
lower in PES group as compared with BMS group (31% 
and 10.4% vs 49.4% and 21.5%; P = 0.01 and P = 0.03, 
respectively). In this post hoc analysis, 9-month MACE 
rates were 18.9% vs 26.9%; P = 0.23, which did not reach 
statistical significance.
In the TAXUS VI trial,30 angiographic and clini-
cal outcomes were followed up to 9 months in complex 
subset of patients. In the subgroup with small vessels 
(RVD , 2.5 mm), in-stent late lumen loss was consider-
ably smaller in the PES group than in the BMS group 
(0.23 ± 0.45 mm vs 0.95 ± 0.52 mm; P , 0.0001), explain-
ing the significantly lower angiographic restenosis and TLR 
observed in the PES group (7.3% and 5.0% vs 40.4% and 
29.7%, respectively; P , 0.001).
Taking these TAXUS subgroup results in consideration, 
PES seems to confer clinical benefits in patients with small 
vessels compared with BMS. This is mainly because of 
marked inhibition of neointimal hyperplasia by PES. These 
results could have been influenced by the release kinetics of 
drug, polymer used, and stent platform. TAXUS® Express® 
stent (Boston Scientific Inc, Natick, Massachusetts) was used 
in TAXUS IV trial, and TAXUS Express2 stent was used 
in TAXUS V and TAXUS VI trials. TAXUS Express stent 
consists of balloon-expandable stent with Translute™ 
polymer-coating containing paclitaxel (Boston Scientific Inc). 
TAXUS Express2 stent is composed of a balloon-expandable 
Express2 stent with a triblock copolymer   coating with pacli-
taxel. The release kinetics of drug was slow in TAXUS IV and 
V trials, whereas this was moderate in TAXUS VI trial.
Sirolimus-eluting stent vs BMS  
in small vessels
Sirolimus-eluting stent (SES) has been tested in pivotal 
SIRIUS trial,31 and the substudy involving small vessels 
(#2.75 mm) showed significantly lower TLR rates with SES 
as compared with BMS (6.6% vs 22.3%; P , 0.0001). Simi-
larly, angiographic substudy32 has shown significantly lower 
restenosis in SES group (17.6% vs 42.7%; P , 0.001).
The SES-SMART trial,33 which enrolled patients with 
small vessels (mean RVD = 2.2 mm), indicated that the inci-
dence of TLR and MACE in the SES arm was significantly 
lower compared with BMS arm (7.0% and 9.3% vs 21.1% 
and 31.3%; P = 0.002 and P , 0.001, respectively). Angio-
graphic restenosis in the SES arm was also significantly lower 
compared with the BMS arm (9.8% vs 53.1%, P , 0.001).
Lee et al34 evaluated the predictive factors for restenosis 
following implantation of SES in small coronary arteries 
(,2.8 mm) in an observational study. They identified lesion 
length and restenotic lesions as independent predictors of 
angiographic restenosis in small vessels.
Zotarolimus-eluting stent vs BMS  
in small vessels
ENDEAVOR program has assessed the efficacy of 
  zotarolimus-eluting stent (ZES) in patients with CAD. 
ENDEAVOR II35 trial has randomly assessed outcomes after 
ZES and BMS in patients with native CAD. In a subgroup anal-
ysis of patients who had angiographic follow-up at 8 months, 
results were reported for 371 patients with RVD , 3 mm. 
There were significantly less angiographic restenosis rates 
with the use of ZES in both ,2.5-mm and 2.5–3 mm 
group as compared with BMS (18.2% vs 38.6%; odds 
ratio [OR] = 0.47; 95% confidence interval [CI]:   0.28–0.79 
in ,2.5-mm group and 4.6% vs 35.1%; OR = 0.13; 95% CI: 
0.05–0.32 in 2.5–3.0 mm group, respectively). They have 
also reported significantly less TLR rate with the use of ZES 
as compared with BMS (7.2% vs 16.5% in ,2.5-mm group 
and 3.0% vs 11.5% in 2.5–3.0 mm group).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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PES vs SES in small vessels
There is limited information available comparing SES and 
PES in small vessels. Some trials comparing the outcomes 
in small vessels are shown in Table 2. ISAR-SMART 336 was 
the first head-to-head trial comparing SES and PES. This trial 
showed significantly less angiographic restenosis and TLR 
rates with the use of SES as compared with PES (11.4% and 
6.6% vs 19.0% and 14.7%, respectively).
More recently, subgroup analysis of SIRTAX trial,37 
which included patients with RVD , 2.75 mm was reported. 
In patients with small vessel stents, SES reduced MACE 
by 55% (10.4% vs 21.4%; P = 0.004), mainly driven by a 
69% reduction of TLR rate (6.0% vs 17.7%; P = 0.001). 
However, there were no significant differences with respect 
to death and MI.
There are two nonrandomized trials that have been per-
formed comparing SES and PES in small coronary vessels. 
Park et al38 have performed retrospective study involving 197 
patients with RVD of nearly 2.45 mm and reported lower 
angiographic restenosis and TLR rates with the use of SESs 
(6.7% and 3.3% vs 27.7% and 14.4%; P , 0.01). Another 
RESEARCH and T-SEARCH39,40 registry adopted a nonran-
domized design and evaluated outcomes in patients treated with 
SES and PES in small coronary   vessels (RVD = 2.25 mm). 
The incidence of 12-month TLR and MACE was numerically 
more frequent with the use of PES, but they did not reach 
statistical significance (11.1% and 18.9% vs 6.5% and 9.3%; 
P = 0.31) and P = 0.06, respectively.
ZES vs PES in small vessels
ENDEAVOR IV41 compared outcomes following implanta-
tion of ZES and PES in patients with CAD. In a subgroup 
analysis involving small vessels (,2.5 mm), there was signifi-
cantly less target vessel failure at 12 months with the use of 
ZES as compared with PES (8.3% vs 13.4%; OR = 0.62; 95% 
CI: 0.37–1.03). However, there was no difference observed 
between PES and ZES in 2.5–3 mm group (8.8% vs 7.5%; 
OR = 1.18; 95% CI: 0.69–2.04).
Everolimus-eluting stent vs PES  
in small vessels
SPRIT IV42 trial has compared the efficacy of everolimus-
eluting stent (EES) and PES in patients with CAD. In a 
whole cohort, 1,352 patients were treated for small vessel 
disease (#2.75 mm). In this subgroup analysis, there was 
  significantly less occurrence of target vessel failure with the 
use of EES as compared with PES (3.9% vs 6.8%; OR = 0.57; 
95% CI: 0.35–0.91).
Biolimus-eluting stent vs SES  
in small vessels
LEADERS trial43 compared biolimus-eluting stent (BES) 
with biodegradable polymer and SES with durable polymer in 
patients with CAD. In a substudy, investigators have assessed 
the impact of vessel size on outcomes with these two dif-
ferent stent strategies. All-comer patients (1,707 patients) 
were included in the study, and comparison was done 
between vessel size ,2.75 mm (50.0% of the total cohort) 
and .2.75 mm. There was no significant difference between 
TLR rate (9.6% vs 7.4%; P = 0.26) and MACE (12.1% 
vs 11.8%; P = 0.89) in both BES and SES arms. However, 
the TLR rate (9.6% vs 2.6%) and MACE (12.7% vs 7.1%) 
were significantly higher in small vessels as compared with 
large vessels in the BES arm.
Summary of impact of DES  
in small vessels
As evident from the aforementioned studies, the   outcomes 
in small coronary arteries have improved following 
the   introduction of DESs. TLR rate has improved from 
Table 2 Comparison of angiographic characteristics, death, MI, TLR, and MACEs, following SES and PES
Study Total No. of 
patients
RVD (mm) SES vs PES
Death (%) MI (%) TLR (%) MACE (%)
ISAR-SMART 336 360 ,2.75 1.7 vs 2.2 
P = 0.99
3.9 vs 3.3 
P = 0.78
6.6 vs 14.7 
P = 0.008
Park et al38 197 ,2.75 0 vs 0 
P = 1
12.4 vs 13.2 
P = 0.54
3.3 vs 14.4 
P , 0.01
15.7 vs 27.6 
P , 0.01
RESEARCH and  
T-SEARCH39,40
199 ,2.25 0.9 vs 4.3 
P = 0.18
2.8 vs 7.8 
P = 0.19
6.5 vs 11.1 
P = 0.31
9.3 vs 18.9 
P = 0.06
SIRTAX37 370 ,2.75 6.0 vs 5.4 
OR = 1.10; 95% 
CI, 0.47–2.60
3.8 vs 3.7 
OR = 1.01; 95% 
CI, 0.35–2.88
6.0 vs 17.7 
OR = 0.31; 95%  
CI, 0.16–0.62
10.4 vs 20.4 
OR = 0.45; 95% 
CI, 0.26–0.78
Abbreviations: MI, myocardial infarction; TLR, target lesion revascularization; MACEs, major adverse cardiac events; RVD, reference vessel diameter; SES, sirolimus-eluting 
stent; PES, paclitaxel-eluting stent; OR, odds ratio; CI, confidence interval.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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20%–30% in the BMS era to around 10% with the usage of 
various DESs. This still remains higher as compared with 
other subgroups of CAD. Among the various DESs   available, 
the TLR rate is relatively low (3%–7%) with the use of EES 
and SES as compared with PES and ZES (8%–13%). These 
results are biologically plausible because a reduction in 
  luminal   diameter by a constant amount of neointimal hyper-
plasia results in proportionally higher-grade diameter stenosis 
in small vessels compared with large vessels. Moreover, EES 
and SES have been invariably shown to afford lower late 
luminal loss in the trials (0.14 ± 0.41 mm for EES in SPIRIT 
III44 trial and 0.16 ± 0.30 mm for SES in pivotal trials) as 
compared with higher late luminal loss with the use of ZES 
and PES (0.67 ± 0.49 mm for ZES and 0.42 ± 0.50 mm for 
PES in ENDEAVOR IV and 0.61 ± 0.46 mm in ENDEAVOR 
III),45 and a late luminal loss is an established marker to 
discriminate between different stent types.46
Influence of stent strut thickness  
on outcomes in small vessels
The mechanical differences of the BMS and the DESs may 
affect the outcomes in small coronary arteries. Briguori 
et al47 have shown that strut thickness was an independent 
predictor of angiographic restenosis in small coronary 
  arteries (RVD = 2.75–2.99 mm); thinner-strutted stents 
were   associated with lower incidence of restenosis than 
  thicker-strutted stents.
Brambilla et al48 have assessed that in a prospective, 
  multicentre registry, the impact of thin-strut chrome–cobalt 
stent (Mini VISION-strut size 0.081 mm) angiographic and 
clinical outcomes in small coronary vessels. The   average 
RVD was 2.41 ± 0.41 mm, and the 6 months MACE 
was 11.6%, death 2.9%, MI 2.9%, and TLR 5.8%. These 
  outcomes are comparable with DES outcomes.
TAXUS ATLAS Small Vessel (SV) program49 is a 
multicentre study comparing the performance of the thin-
strut (0.095 mm) TAXUS Liberte® 2.25-mm stent (Boston 
Scientific Inc) in small vessels. This study compared the 
outcomes following implantation of TAXUS Liberte and 
TAXUS Express (0.132-mm strut size) stents in small vessels. 
TAXUS Liberte significantly reduced the rate of 9-month 
angiographic restenosis (18.5% vs 32.7%; P = 0.02) and 
12-month TLR (6.1% vs 16.9%; P = 0.0003) as compared 
with TAXUS Express stents. This TAXUS liberte (Atom™; 
Boston Scientific Inc) stent was specially designed for small 
vessels (,2.25 mm) and was approved by the US Food 
and Drug Administration for the treatment. This stent has 
27-inch thinner struts, and the unique, uniform repeating   
cell geometry supports even drug distribution and delivery. 
This stent also has lowest stent crossing and tip profile   making 
it a more trackable stent delivery system.
Safety issue following small vessel 
DES implantation
Since DESs were approved, these devices have been 
implanted in a large number of patients with CAD and 
with off-label indications including small vessels. Their 
use seems to be safe. However, issue of stent thrombosis 
has been one of the concerns. Although BMS implantation 
in small vessels had been previously cited as a risk factor 
for stent thrombosis,50–52 improved techniques of optimal 
stent   deployment and dual antiplatelet therapy appear to 
have largely resolved this problem so that the risk of stent 
thrombosis of BMS in small vessel stenting now seems to 
be similar to that in large vessel stenting.53,54
DES implantation in small vessels may increase the risk 
of stent thrombosis. The incidence of stent thrombosis in 
small vessel DES implantation has not been shown to differ 
between PES and BMS or SES. In a subanalysis conducted 
in the TAXUS V29 clinical trial, both acute and late stent 
thrombosis rates were similar between PES and BMS (0.9% vs 
1.1% and 1.0% vs 1.1%; P = 1.00 and P = 1.00,   respectively). 
In   ISAR-SMART 336 trial and a study by Park et al38 no acute 
stent thrombosis was reported in both SES and PES arms, 
whereas there was no information about late stent thrombo-
sis in either trial. In a subanalysis of the RESEARCH and 
T-SEARCH39,40 registries, 2.2% of patients had acute stent 
thrombosis in the PES arm; no thrombosis was observed in 
the SES arm (P = 0.21). No late stent thrombosis occurred in 
either arm. In SIRTAX37 trial there was similar stent thrombo-
sis seen in SES and PES arms in small vessels (2.2% vs 2.7%; 
P = 0.75, respectively). This was similar to the stent thrombo-
sis rates seen in large vessels (1.9% vs 3.3%; P = 0.35) with 
the use of SES and PES, respectively. Lee et al34 have reported 
the late stent thrombosis of 0.4% up to 20 months following 
implantation of SES in small vessels.
However, late stent thrombosis is multifactorial, and the 
limited data available so far have shown similar rates with 
the use of DES.
Factors predictive of adverse 
outcome after DES in small vessels
Revascularization of small coronary arteries has been 
problematic because of high risk of restenosis. Before the 
introduction of DES, the restenosis rate in these lesions 
was very high, ranging from 30%–50%, and there was Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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only marginal benefit from stent implantation. However, 
DESs have markedly reduced the risk of restenosis, and 
their benefits are evident in small vessels. Small vessel 
disease still remains because of DES failure as compared 
with other groups. Lee et al34 have evaluated the predictive 
  factors of adverse outcome following implantation of SES in 
a consecutive series of 1,092 patients with reference vessel 
size ,2.8 mm. They have reported significant correlation 
between restenosis rate and lesion length, and restenosis 
rate was highest (29.4%) in patients with very long lesions 
(.60 mm). Multivariate analysis showed that lesion length 
(OR = 1.04; 95% CI: 1.02–1.05; P , 0.001) and in-stent 
restenotic lesions (OR = 3.38; 95% CI: 1.80–6.35; P , 0.001) 
were significant predictors of restenosis, but diabetes was not 
shown to be significant predictor of restenosis (OR = 0.79, 
95% CI: 0.47–1.33, P = 0.378).
Small vessel disease has become more common, and 
the proportion of patients requiring coronary intervention is 
likely to further increase. However, these patients have higher 
clinical and angiographic restenosis rates following small 
vessel angioplasty as shown in the aforementioned data. The 
risk of complications and restenosis in many of these patients 
are increased by other factors, particularly   diffuse disease 
and diabetes mellitus. Although BMS have an advantage in 
acute gain compared with balloon   angioplasty, the former 
results in more late loss due to neointimal   overgrowth. This 
tissue encroachment presents a greater problem in small than 
in large vessels because it leaves less room for the lumen in 
the former. Therefore, using BMS, the long-term results of 
small vessel stenting were   disappointing, and provisional 
stenting was considered a better option. The use of DESs 
in small coronary arteries, however, has reduced the rate of 
restenosis in comparison to BMSs. Various types of DESs 
are widely used in clinical practice. In head-to-head studies, 
the SES and EES have shown lower rate of late lumen loss 
as compared with PES and ZES, suggesting that the former 
group may be more   effective in preventing restenosis in 
high-risk patients.
Future directions in small vessel 
coronary angioplasty
A number of stent-related properties, including stent con-
figuration, strut thickness, and stent coating, can affect the 
long-term clinical outcome. Many trials have shown that 
the mesh-wire and coil-related stent designs suffer from 
a significantly higher risk of restenosis compared with the 
tubular or multicellular stent design. Studies have shown that 
stent with less strut–strut intersections (Multilink stent) is 
associated with the most favorable angiographic and   clinical 
  outcomes.55 The design, material composition, surface 
features of the stent, and stent deployment technique affect 
strongly the acute performance of the stent, risk of stent 
thrombosis, degree of vascular response, and subsequent 
risk of in-stent restenosis.
The availability of new, highly biocompatible, and more 
radiovisible alloys with the same if not superior tensile 
strength than stainless steel will enable the production of low 
metal density stents that may further improve the anatomical 
and clinical outcomes of current stainless steel stents. Drug 
elution from these stent platforms could further improve the 
outcomes in small vessels. In future, different stent designs 
and variable strut thickness with different drug elutions need 
to be tested in small coronary vessels.
Conclusion
We have reviewed balloon angioplasty and the placement 
of BMS and different DESs in small vessels with respect 
to clinical outcomes. We could conclude that (1) small ves-
sel coronary angioplasty is common; (2) DES considerably 
reduces the incidence of angiographic restenosis and TLR as 
compared with BMS; and (3) a trend is observed with regard 
to better angiographic and clinical outcomes of EES and SES 
over PES and ZES but with similar safety profile. Stent design 
and strut thickness along with DES influence the outcomes in 
small coronary vessels similar to other coronary lesions.
Large size, randomized, controlled, double-blinded multi-
center trials with long-term follow-up are needed to evaluate 
different DESs and designs in small vessel CAD.
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